CLAIMS

1. A solid pharmaceutical formulation comprising (a) cilostazol~~an active medical ingredient~~, (b) a pregelatinized starch in an amount of 10 to 90 % by weight based on the whole weight of the formulation, ~~and~~ (c) one or more kinds of enteric ingredients and (d)~~.~~

~~2. The solid pharmaceutical formulation of claim 1 wherein the active medical ingredient is a hardly soluble medicament.~~

~~3. The solid pharmaceutical formulation of claim 1 wherein the active medical ingredient is cilostazol.~~

~~4. The solid pharmaceutical formulation of any one of claims 1 to 3 wherein the one or more kinds of enteric ingredients comprise hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, carboxymethylethylcellulose, methacrylic acid copolymer L and/or methacrylic acid copolymer S.~~

~~5. The solid pharmaceutical formulation of any one of claims 1 to 3 wherein the one or more kinds of enteric ingredients are two or more kinds of enteric ingredients that have different pH ranges at which each enteric ingredient can be dissolved.~~

~~6. The solid pharmaceutical formulation of claim 5 wherein the two or more kinds of enteric ingredients are selected from the group consisting of hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, carboxymethylethylcellulose,~~

~~methacrylic acid copolymer L, methacrylic acid copolymer S, and methacrylic acid copolymer LD.~~

~~7. The solid pharmaceutical formulation of claim 5 wherein the two or more kinds of enteric ingredients are the following two kinds of enteric ingredients; one can be dissolved at the pH of 5 or more, and the other one can be dissolved at the pH of 6 or more.~~

~~8. The solid pharmaceutical formulation of claim 5 wherein the two or more kinds of enteric ingredients are the following two kinds of enteric ingredients; one can be dissolved at the pH of 6 or more, and the other one can be dissolved at the pH of 7 or more.~~

~~9. The solid pharmaceutical formulation of claim 4 wherein the one or more kinds of enteric ingredients comprise methacrylic acid copolymer L and methacrylic acid copolymer S.~~

~~10. The solid pharmaceutical formulation of claim 9 wherein the ratio of methacrylic acid copolymer L and methacrylic acid copolymer S is 30:70 to 70:30.~~

~~11. The solid pharmaceutical formulation of any one of claims 1 to 10 further comprising~~ an organic acid.

~~1~~2. The solid pharmaceutical formulation of claim 1~~1~~ wherein the organic acid is contained in 0.5 to 5 % by weight.

~~1~~3. The solid pharmaceutical formulation of claim 1~~1~~ or ~~1~~2 wherein the organic acid is citric acid.

4. The solid pharmaceutical formulation of any one of claims 1 to 3 wherein the one or more kinds of enteric ingredients comprise hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, carboxymethylethylcellulose, methacrylic acid copolymer L and/or methacrylic acid copolymer S.

5~~14~~. The solid pharmaceutical formulation of claim ~~1~~3 wherein the enteric ingredients comprise methacrylic acid copolymer S.

6~~15~~. The solid pharmaceutical formulation of any one of claims 1 to 5~~14~~ wherein the pre-gelatinized starch is pre-gelatinized corn starch.

7~~16~~. The solid pharmaceutical formulation of any one of claims 1 to 6~~15~~ which is prepared by the following steps (i) and (ii):

(i) mixing cilostazol~~an active medical ingredient~~, a starch, ~~and~~ one or more kinds of enteric ingredients and an organic acid to prepare a starting composition, and

(ii) subjecting the starting composition to a pre-gelatinization of starch.

8~~17~~. The solid pharmaceutical formulation of claim 7~~16~~ wherein the starch in (i) is one or a mixture consisting of a starch, a partly pre-gelatinized starch and/or a pre-gelatinized starch, provided that the starch in (i) is not only a pre-gelatinized starch.

9~~18~~. The solid pharmaceutical formulation of any one of claims 1 to 8~~17~~ which is in the form of a particle.

10~~19~~. The solid pharmaceutical formulation of any one of claims 1 to 8~~17~~ which is in the form of a granule or a powder.

11~~20~~. The solid pharmaceutical formulation of claim 10~~19~~ which is prepared by an extrusion granulation technique.

12~~21~~. A capsule formulation which comprises the solid pharmaceutical formulation of claims 9~~18~~, 10~~19~~ and/or 11~~20~~.

13~~22~~. A tablet formulation which comprises the solid pharmaceutical formulation of claims 9~~18~~, 10~~19~~ and/or 11~~20~~.

14~~23~~. A method for preparing the solid pharmaceutical formulation of any one of claims 1 to 11~~20~~, wherein the starch is pre-gelatinized by heating during the process of the preparation.

15~~24~~. The method of claim 14~~23~~ wherein the heating is accompanied with humidification.

16~~25~~. The~~A~~ solid pharmaceutical formulation of any one of claims 1 to 11 which is prepared by the method of claim 14~~23~~ or 15~~24~~.

17~~26~~. A capsule formulation which is filled with a rapidly-release granule or powder containing cilostazol~~an active medical ingredient~~, and the particle, granule or powder of any one or more of claims 9~~18~~ to 11~~20~~.